0001209191-20-031872.txt : 20200522
0001209191-20-031872.hdr.sgml : 20200522
20200522185533
ACCESSION NUMBER: 0001209191-20-031872
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200520
FILED AS OF DATE: 20200522
DATE AS OF CHANGE: 20200522
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gasmi Mehdi
CENTRAL INDEX KEY: 0001614875
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36579
FILM NUMBER: 20907552
MAIL ADDRESS:
STREET 1: C/O AVALANCHE BIOTECHNOLOGIES, INC.
STREET 2: 1035 O'BRIEN DRIVE, SUITE A
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adverum Biotechnologies, Inc.
CENTRAL INDEX KEY: 0001501756
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 205258327
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 800 SAGINAW DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-272-6269
MAIL ADDRESS:
STREET 1: 800 SAGINAW DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
FORMER COMPANY:
FORMER CONFORMED NAME: Avalanche Biotechnologies, Inc.
DATE OF NAME CHANGE: 20100921
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-05-20
0
0001501756
Adverum Biotechnologies, Inc.
ADVM
0001614875
Gasmi Mehdi
C/O ADVERUM BIOTECHNOLOGIES, INC.
800 SAGINAW DRIVE
REDWOOD CITY
CA
94063
1
0
0
0
Common Stock
2020-05-20
4
M
0
1401
4.80
A
275843
D
Common Stock
2020-05-20
4
S
0
1401
20.0071
D
274442
D
Common Stock
2020-05-21
4
M
0
3599
4.80
A
278041
D
Common Stock
2020-05-21
4
S
0
3599
20.0189
A
274442
D
Stock Option (Right to Buy)
4.80
2020-05-20
4
M
0
1401
0.00
D
2026-02-11
Common Stock
1401
131599
D
Stock Option (Right to Buy)
4.80
2020-05-21
4
M
0
3599
0.00
D
2026-02-11
Common Stock
3599
128000
D
Shares sold pursuant to a 10b5-1 plan.
Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.00 to $20.03. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Price reported is a weighted-average sales price. The shares were sold at prices ranging from $20.00 to $20.05. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Fully vested and exercisable.
Mehdi Gasmi, by /s/ Peter Soparkar, Attorney-in-Fact
2020-05-22